WAT - Waters acquires charge detection mass spectrometry technology

Waters (NYSE:WAT) has acquired technology assets and intellectual property rights of Megadalton Solutions, an early-stage developer of charge detection mass spectrometry (CDMS). CDMS overcomes limitations of conventional mass spectrometry in characterizing complex large molecules in cell and gene therapies. CDMS technology will be further developed to extend capabilities of Waters’ mass spectrometry portfolio for broader set of applications and potential customers. Waters became a strategic investor in the company and in 2021 brought Megadalton’s CDMS technology into the Waters Immerse™ Cambridge innovation and research lab for advanced testing and development. Financial details of the transaction are not being disclosed.

For further details see:

Waters acquires charge detection mass spectrometry technology